SCHEMBL21611958

SCHEMBL21611958

N#Cc1ccc(-n2cc(CNc3ccnc(C(F)(F)F)c3)nn2)cc1

nearest known ligand 0.69

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.69
▸ CYP2C19 P33261 1/20 0.69
▸ NOTUM Q6P988 1/20 0.49
▸ RXRA P19793 13/20 0.47
▸ GRIN1 Q05586 13/20 0.47
▸ GRIN2B Q13224 13/20 0.47
▸ KDM1A O60341 1/20 0.46
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ MAP3K8 P41279 2/20 0.40
▸ TGFBR1 P36897 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21614644 0.87 CYP3A4 (0.74) CYP3A4CYP2C19RXRAGRIN1GRIN2B
SCHEMBL21611968 0.87 CYP3A4 (0.74) CYP3A4CYP2C19NOTUMRXRAGRIN1
SCHEMBL21612038 0.86 CYP3A4 (0.73) CYP3A4CYP2C19NOTUMRXRAGRIN1
SCHEMBL21614670 0.86 CYP3A4 (0.73) CYP3A4CYP2C19NOTUMRXRAGRIN1
SCHEMBL21614651 0.83 CYP3A4 (0.69) CYP3A4CYP2C19RXRAGRIN1GRIN2B
SCHEMBL21611991 0.83 CYP3A4 (0.78) CYP3A4CYP2C19RXRAGRIN1GRIN2B
SCHEMBL21614635 0.83 CYP3A4 (0.78) CYP3A4CYP2C19RXRAGRIN1GRIN2B
SCHEMBL21614640 0.83 CYP3A4 (0.78) CYP3A4CYP2C19RXRAGRIN1GRIN2B
SCHEMBL21614679 0.83 CYP3A4 (0.68) CYP3A4CYP2C19RXRAGRIN1GRIN2B
SCHEMBL21614738 0.82 CYP3A4 (0.68) CYP3A4CYP2C19NOTUMRXRAGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
EP-3818045-A1 PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-05-12 — — EP disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353606-A1 PqsR INVERSE AGONISTS QRFPR, P2RY11, QARS1 CYP3A4 3080/4885CYP2C19 1824/4885NOTUM 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback